ElSayed NA, Aleppo G, Aroda VR, et al. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S140–57.

Article  CAS  PubMed  Google Scholar 

Noseworthy T, Clement F. Health technology reassessment: scope, methodology, and language. Int J Technol Assess Health Care. 2012;28(3):201–2.

Article  PubMed  Google Scholar 

Liu AYL, Low S, Yeoh E, et al. A real-world study on SGLT2 inhibitors and diabetic kidney disease progression. Clin Kidney J. 2022;15(7):1403–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Idris I, Zhang R, Mamza JB, et al. Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: a retrospective cohort study in UK primary care. Diabetes Obes Metab. 2021;23(10):2207–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Young KG, McInnes EH, Massey RJ, et al. Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: a systematic review. Commun Med. 2023;3(1):131.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Birkeland KI, Jørgensen ME, Carstensen B, et al. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes Endocrinol. 2017;5(9):709–17.

Article  CAS  PubMed  Google Scholar 

Peng Z-Y, Yang C-T, Ou H-T, et al. Cost-effectiveness of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors among patients with type 2 diabetes with and without established cardiovascular diseases: a model-based simulation analysis using 10-year real-world data and targeted literature review. Diabetes Obes Metab. 2022;24(7):1328–37.

Article  CAS  PubMed  Google Scholar 

McEwan P, Bennett H, Khunti K, et al. Assessing the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: a comprehensive economic evaluation using clinical trial and real-world evidence. Diabetes Obes Metab. 2020;22(12):2364–74.

Article  CAS  PubMed  Google Scholar 

Li X, Hoogenveen R, El Alili M, et al. Cost-effectiveness of SGLT2 inhibitors in a real-world population: a MICADO model-based analysis using routine data from a GP registry. Pharmacoeconomics. 2023;41(10):1249–62.

Article  PubMed  PubMed Central  Google Scholar 

Igarashi A, Maruyama-Sakurai K, Kubota A, et al. Cost-effectiveness analysis of initiating type 2 diabetes therapy with a sodium-glucose cotransporter 2 inhibitor versus conventional therapy in Japan. Diabetes Ther. 2022;13(7):1367–81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sim R, Chong CW, Loganadan NK, et al. Cost-effectiveness of glucose-lowering therapies as add-on to standard care for people with type 2 diabetes in Malaysia. Value Health Reg Issues. 2023;38:9–17.

Article  PubMed  Google Scholar 

Breeze P, Brennan A. Valuing trial designs from a pharmaceutical perspective using value-based pricing. Health Econ. 2015;24(11):1468–82.

Article  PubMed  Google Scholar 

Garrison LP Jr, Pauly MV, Willke RJ, et al. An overview of value, perspective, and decision context-a health economics approach: an ISPOR special task force report [2]. Value Health. 2018;21(2):124–30.

Article  PubMed  Google Scholar 

Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.

Article  CAS  PubMed  Google Scholar 

Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–57.

Article  CAS  PubMed  Google Scholar 

Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57.

Article  CAS  PubMed  Google Scholar 

Chong KS, Chang YH, Lin MH, et al. Kidney outcomes with SGLT2is for type 2 diabetes patients: does background treatment with metformin or RASis matter? Front Endocrinol (Lausanne). 2024;15:1329945.

Article  PubMed  Google Scholar 

Yang CT, Yao WY, Ou HT, et al. Value of GLP-1 receptor agonists versus long-acting insulins for type 2 diabetes patients with and without established cardiovascular or chronic kidney diseases: a model-based cost-effectiveness analysis using real-world data. Diabetes Res Clin Pract. 2023;198:110625.

Article  CAS  PubMed  Google Scholar 

Yang CT, Chong KS, Wang CC, et al. Adaptation of risk prediction equations for cardiovascular outcomes among patients with type 2 diabetes in real-world settings: a cross-institutional study using common data model approach. Cardiovasc Diabetol. 2024;23(1):244.

Article  PubMed  PubMed Central  Google Scholar 

Life table of the Taiwanese population in 2020. Ministry of the Interior, Taiwan. https://www.moi.gov.tw/cl.aspx?n=2948.Accessed 1 Mar 2022.

Liu CS, Li CI, Wang MC, Yang SY, Li TC, Lin CC. Building clinical risk score systems for predicting the all-cause and expanded cardiovascular-specific mortality of patients with type 2 diabetes. Diabetes Obes Metab. 2021;23(2):467–79.

Article  CAS  PubMed  Google Scholar 

Chiang JI, Hanlon P, Li TC, et al. Multimorbidity, mortality, and HbA1c in type 2 diabetes: a cohort study with UK and Taiwanese cohorts. PLoS Med. 2020;17(5):e1003094.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang CT, Peng ZY, Chen YC, Ou HT, Kuo S. Cardiovascular benefits with favorable renal, amputation and hypoglycemic outcomes of SGLT-2 inhibitors in type 2 diabetes from the Asian perspective: a population-based cohort study and systematic review. Front Endocrinol (Lausanne). 2022;13:836365.

Article  PubMed  Google Scholar 

Kuo S, Yang CT, Chen HY, et al. Valuing health states of people with type 2 diabetes: analyses of the nationwide representative linked databases. J Diabetes Investig. 2021;12(9):1749–58.

Article  PubMed  PubMed Central  Google Scholar 

Chen HY, Kuo S, Su PF, et al. Health care costs associated with macrovascular, microvascular, and metabolic complications of type 2 diabetes across time: estimates from a population-based cohort of more than 0.8 million individuals with up to 15 years of follow-up. Diabetes Care. 2020;43(8):1732–40.

Article  PubMed  PubMed Central  Google Scholar 

List of reimbursed drugs by NHI. https://www.nhi.gov.tw/QueryN_New/QueryN/Query1. Accessed 28 Dec 2023.

Medication utilization analysis. National Health Insurance Administration, Ministry of Health and Welfare, Taiwan. https://www.nhi.gov.tw/ch/cp-2297-94173-2514-1.html. Accessed 28 Dec 2023.

Medical consumer price index in Taiwan. National Statistics, R.O.C. (Taiwan). https://nstatdb.dgbas.gov.tw/dgbasAll/webMain.aspx?sys=100&funid=dgmaine. Accessed 28 Dec 2023.

Health Technology Assessment of Center for Drug Evaluation, Taiwan. Taiwan Guidelines of Methodological Standards for Pharmacoeconomic Evaluation. https://www.cde.org.tw/HTA/history. Accessed 28 Dec 2022.

Bertram MY, Lauer JA, De Joncheere K, et al. Cost-effectiveness thresholds: pros and cons. Bull World Health Organ. 2016;94(12):925–30.

Article  PubMed  PubMed Central  Google Scholar 

Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093–103.

Article  PubMed  Google Scholar 

Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health. 2022;25(1):3–9.

Article  PubMed  Google Scholar 

Palmer AJ, Si L, Tew M, et al. Computer modeling of diabetes and its transparency: a report on the eighth mount hood challenge. Value Health. 2018;21(6):724–31.

Article  PubMed  PubMed Central  Google Scholar 

Pasternak B, Ueda P, Eliasson B, et al. Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study. BMJ. 2019;366:l4772.

Article  PubMed  PubMed Central